Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Axsome Thera
(NQ:
AXSM
)
87.99
+0.88 (+1.01%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axsome Thera
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
3 Biotech Stocks That Could Be Millionaire Makers
November 22, 2023
Many biotech stocks offer exciting long-term growth prospects.
Via
The Motley Fool
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
November 21, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Analyst Expectations for Axsome Therapeutics's Future
November 07, 2023
Via
Benzinga
Earnings Scheduled For November 6, 2023
November 06, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Via
Benzinga
Analyst Ratings for Axsome Therapeutics
September 25, 2023
Via
Benzinga
2 Top Biotech Stocks Defying the Bear Market
September 15, 2023
The best may be yet to come for these companies.
Via
The Motley Fool
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
November 18, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
November 17, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers – AXSM
November 16, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
2 No-Brainer Biotech Stocks to Buy Right Now
September 12, 2023
You can get in early on these potential winners.
Via
The Motley Fool
3 Growth Stocks to Buy Right Now Without Any Hesitation
November 11, 2023
Investors shouldn't have to deliberate for too long about these great stocks.
Via
The Motley Fool
3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates
November 09, 2023
Can these promising growth stocks continue rising in value?
Via
The Motley Fool
Topics
Economy
Exposures
Interest Rates
Axsome's Strategy on Payer Coverage Slowly Pays Off, Depression Drug Sales Show Growth
November 06, 2023
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q3 revenues of $57.8 million, up 244% Y/Y, beating the consensus of $54.75 m
Via
Benzinga
Axsome Therapeutics (AXSM) Q3 2023 Earnings Call Transcript
November 06, 2023
AXSM earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 06, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023
November 02, 2023
Axsome’s headquarters to be lit in teal as part of the Alzheimer’s Foundation of America awareness campaign
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at Upcoming Investor Conferences
October 31, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Riding the Wave: 3 Stocks That Can 10X by 2025
October 30, 2023
Are you looking to invest in stocks with the potential to 10x? Here are three stocks that can 10x by 2025.
Via
InvestorPlace
Got $2,000? Here Are 2 Beaten-Down Growth Stocks to Buy Right Now
October 27, 2023
Now, you can scoop up these future growth winners for a bargain.
Via
The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
October 25, 2023
Neither has performed well on the stock market this year.
Via
The Motley Fool
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference
October 24, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
3 No-Brainer Stocks to Buy Right Now for Less than $100
October 23, 2023
You can start with a small investment and win big over time.
Via
The Motley Fool
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
October 11, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
October 10, 2023
Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
2 Top Biotech Stocks to Buy in October
October 03, 2023
Growth catalysts lie ahead for both of these players.
Via
The Motley Fool
Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week
October 02, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
September 28, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
September 27, 2023
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.
Via
Investor's Business Daily
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
September 21, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.